Bandelow, Borwin

[["dc.bibliographiccitation.journal","European Neuropsychopharmacology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Stein, D. J."],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Dolberg, Ornah T."],["dc.contributor.author","Despiegel, N."],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T09:18:50Z"],["dc.date.available","2018-11-07T09:18:50Z"],["dc.date.issued","2006"],["dc.format.extent","S468"],["dc.identifier.doi","10.1016/S0924-977X(06)70618-6"],["dc.identifier.isi","000240771302025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28492"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","19th Congress of the European-College-of-Neuropsychopharmacology"],["dc.relation.eventlocation","Paris, FRANCE"],["dc.relation.issn","0924-977X"],["dc.title","Which factors predict placebo response in anxiety disorders and major depression?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","567"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Psychopharmacology"],["dc.bibliographiccitation.lastpage","596"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Anderson, Ian M."],["dc.contributor.author","Nutt, D. J."],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Bond, A."],["dc.contributor.author","Davidson, JRT"],["dc.contributor.author","den Boer, Johan A."],["dc.contributor.author","Fineberg, Naomi A."],["dc.contributor.author","Knapp, M."],["dc.contributor.author","Scott, J."],["dc.contributor.author","Wittchen, Hans-Ulrich"],["dc.date.accessioned","2018-11-07T10:54:44Z"],["dc.date.available","2018-11-07T10:54:44Z"],["dc.date.issued","2005"],["dc.description.abstract","These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments."],["dc.identifier.doi","10.1177/0269881105059253"],["dc.identifier.isi","000233135400002"],["dc.identifier.pmid","16272179"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49631"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.relation.issn","1461-7285"],["dc.relation.issn","0269-8811"],["dc.title","Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","39"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Allgulander, Christer"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Costa, Daniel Lucas da Conceição"],["dc.contributor.author","Denys, Damiaan"],["dc.contributor.author","Dilbaz, Nesrin"],["dc.contributor.author","Domschke, Katharina"],["dc.contributor.author","Eriksson, Elias"],["dc.contributor.author","Fineberg, Naomi A."],["dc.contributor.author","Hättenschwiler, Josef"],["dc.contributor.author","Zohar, Joseph"],["dc.date.accessioned","2022-09-01T09:50:25Z"],["dc.date.available","2022-09-01T09:50:25Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1080/15622975.2022.2086295"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113705"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1814-1412"],["dc.relation.issn","1562-2975"],["dc.title","World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","239"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Human Psychopharmacology Clinical and Experimental"],["dc.bibliographiccitation.lastpage","253"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Muscatello, Maria Rosaria"],["dc.contributor.author","Spina, Edoardo"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Baldwin, David S."],["dc.date.accessioned","2018-11-07T09:10:43Z"],["dc.date.available","2018-11-07T09:10:43Z"],["dc.date.issued","2012"],["dc.description.abstract","Objective Certain drugs used in the treatment of patients with anxiety disorders can interact with other psychotropic drugs and with pharmacological treatments for physical illnesses. There is a need for an updated comparative review of clinically relevant drug interactions in this area. Design Relevant literature on drug interactions with medications used in the treatment of anxiety disorders was identified through a search in MEDLINE and EMBASE. Results Drug interactions involving medications used to treat anxiety disorders may be pharmacokinetic, such as enzyme inhibition or induction in the cytochrome P450 system and transporter-mediated drug interactions, or pharmacodynamic, such as additive effects in causing drowsiness or additive effects at neurotransmitter receptors. Certain selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, and paroxetine) are particularly liable to be potentially involved in untoward pharmacokinetic interactions. Conclusions The potential for drug interactions with medications used in anxiety disorders should be the cause of clinical concern, particularly in elderly individuals. However, the liability for harmful drug interactions may be anticipated, and the risk reduced. Although not all interactions are clinically relevant, careful monitoring of clinical response and possible interactions is essential. Copyright (c) 2012 John Wiley & Sons, Ltd."],["dc.identifier.doi","10.1002/hup.2217"],["dc.identifier.isi","000304042900002"],["dc.identifier.pmid","22311403"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26558"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0885-6222"],["dc.title","Clinically relevant drug interactions in anxiety disorders"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","248"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","312"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Zohar, Joseph"],["dc.contributor.author","Hollander, Eric"],["dc.contributor.author","Kasper, Siegfried"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.contributor.author","Allgulander, Christer"],["dc.contributor.author","Ayuso-Gutierrez, Jose"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Bunevicius, Robertas"],["dc.contributor.author","Cassano, Giovanni"],["dc.contributor.author","Fineberg, Naomi A."],["dc.contributor.author","Gabriels, Loes"],["dc.contributor.author","Hindmarch, Ian"],["dc.contributor.author","Kaiya, Hisanobu"],["dc.contributor.author","Klein, Donald F."],["dc.contributor.author","Lader, Malcolm"],["dc.contributor.author","Lecrubier, Yves"],["dc.contributor.author","Lepine, Jean-Pierre"],["dc.contributor.author","Liebowitz, Michael R."],["dc.contributor.author","Lopez-Ibor, Juan Jose"],["dc.contributor.author","Marazziti, Donatella"],["dc.contributor.author","Miguel, Euripedes C."],["dc.contributor.author","Oh, Kang Seob"],["dc.contributor.author","Preter, Maurice"],["dc.contributor.author","Rupprecht, Rainer"],["dc.contributor.author","Sato, Mitsumoto"],["dc.contributor.author","Starcevic, Vladan"],["dc.contributor.author","Stein, Dan J."],["dc.contributor.author","van Ameringen, Michael"],["dc.contributor.author","Vega, Johann"],["dc.date.accessioned","2018-11-07T11:20:53Z"],["dc.date.available","2018-11-07T11:20:53Z"],["dc.date.issued","2008"],["dc.description.abstract","In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines."],["dc.identifier.doi","10.1080/15622970802465807"],["dc.identifier.isi","263223800002"],["dc.identifier.pmid","18949648"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55644"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Ltd"],["dc.relation.issn","1814-1412"],["dc.relation.issn","1562-2975"],["dc.title","World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","403"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Psychopharmacology"],["dc.bibliographiccitation.lastpage","439"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Anderson, Ian M."],["dc.contributor.author","Nutt, David J."],["dc.contributor.author","Allgulander, Christer"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","den Boer, Johan A."],["dc.contributor.author","Christmas, David M."],["dc.contributor.author","Davies, Simon"],["dc.contributor.author","Fineberg, Naomi A."],["dc.contributor.author","Lidbetter, Nicky"],["dc.contributor.author","Malizia, Andrea"],["dc.contributor.author","McCrone, Paul"],["dc.contributor.author","Nabarro, Daniel"],["dc.contributor.author","O'Neill, Catherine"],["dc.contributor.author","Scott, Jan"],["dc.contributor.author","van der Wee, Nic"],["dc.contributor.author","Wittchen, Hans-Ulrich"],["dc.date.accessioned","2018-11-07T09:40:58Z"],["dc.date.available","2018-11-07T09:40:58Z"],["dc.date.issued","2014"],["dc.description.abstract","This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees."],["dc.identifier.doi","10.1177/0269881114525674"],["dc.identifier.isi","000335115800001"],["dc.identifier.pmid","24713617"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33618"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.relation.issn","1461-7285"],["dc.relation.issn","0269-8811"],["dc.title","Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","426"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","432"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Allgulander, Christer"],["dc.contributor.author","Altamura, Alfredo Carlo"],["dc.contributor.author","Angst, Jules"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","den Boer, Johan A."],["dc.contributor.author","Boyer, Patrice"],["dc.contributor.author","Davies, Simon"],["dc.contributor.author","dell'Osso, Bernardo"],["dc.contributor.author","Eriksson, Elias"],["dc.contributor.author","Fineberg, Naomi A."],["dc.contributor.author","Fredrikson, Mats"],["dc.contributor.author","Herran, Andres"],["dc.contributor.author","Maron, Eduard"],["dc.contributor.author","Metspalu, Andres"],["dc.contributor.author","Nutt, David"],["dc.contributor.author","van der Wee, Nic"],["dc.contributor.author","Luis Vazquez-Barquero, Jose"],["dc.contributor.author","Zohar, Joseph"],["dc.date.accessioned","2018-11-07T08:42:35Z"],["dc.date.available","2018-11-07T08:42:35Z"],["dc.date.issued","2010"],["dc.description.abstract","Despite the size, burden and costs of anxiety disorders, many patients remain unrecognised, and the effectiveness of evidence-based interventions in routine clinical practice can be disappointing. The European College of Neuropsychopharmacology (ECNP) has established the ECNP Network Initiative (ECNP-NI) to help meet the goal of extending current understanding of the causes of central nervous system disorders, thereby contributing to improvements in clinical outcomes and reducing the associated societal burden. The Anxiety Disorders Research Network (ADRN) has been adopted within the ECNP-NI: this consensus statement summarises its overall aims and objectives. (C) 2010 Elsevier B.V. and ECNP. All rights reserved."],["dc.description.sponsorship","ECNP; ECNP-NI"],["dc.identifier.doi","10.1016/j.euroneuro.2010.02.015"],["dc.identifier.isi","000278640300009"],["dc.identifier.pmid","20356717"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19737"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0924-977X"],["dc.title","Manifesto for a European Anxiety Disorders Research Network"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","17"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Allgulander, Christer"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Costa, Daniel Lucas da Conceição"],["dc.contributor.author","Denys, Damiaan"],["dc.contributor.author","Dilbaz, Nesrin"],["dc.contributor.author","Domschke, Katharina"],["dc.contributor.author","Hollander, Eric"],["dc.contributor.author","Kasper, Siegfried"],["dc.contributor.author","Möller, Hans-Jürgen"],["dc.contributor.author","Zohar, Joseph"],["dc.date.accessioned","2022-09-01T09:50:25Z"],["dc.date.available","2022-09-01T09:50:25Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1080/15622975.2022.2086296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113706"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1814-1412"],["dc.relation.issn","1562-2975"],["dc.title","World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Human Psychopharmacology Clinical and Experimental"],["dc.bibliographiccitation.lastpage","275"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Stein, Dan J."],["dc.contributor.author","Dolberg, Ornah T."],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T08:29:19Z"],["dc.date.available","2018-11-07T08:29:19Z"],["dc.date.issued","2009"],["dc.description.abstract","Objective To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo-controlled trials (RCTs) and to infer the optimal duration of initial escitalopram treatment in clinical practice, after which intervention might be reasonable in case of non-response. Methods Post hoc analysis of pooled clinical trial database for escitalopram in MDD (14 studies), GAD (4 studies) and SAD (2 studies). 'Onset' of action was defined as a 20% or more decrease from baseline score in disorder-specific psychopathological rating scales: 'response' as a 50% or more decrease from baseline score. Results In MDD, the probability of responding at week 8 if no onset was apparent at week 2 was 43%; in patients with an onset of effect the probability was nearly 80%. Similar patterns were observed in GAD and SAD. The chance of responding beyond week 4 in MDD, GAD and SAD was 20% or less if no effect had occurred by week 2. Conclusions The pattern of response in these RCTs suggests that in patients with MDD, GAD or SAD in wider clinical practice, a period of at least 4 weeks is worthwhile before considering further intervention. Copyright (C) 2009 John Wiley & Sons, Ltd."],["dc.identifier.doi","10.1002/hup.1019"],["dc.identifier.isi","000267409700002"],["dc.identifier.pmid","19334042"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16620"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","0885-6222"],["dc.title","How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1741"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","1746"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Stein, Dan J."],["dc.contributor.author","Baldwin, David S."],["dc.contributor.author","Dolberg, Ornah T."],["dc.contributor.author","Despiegel, Nicolas"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T09:01:49Z"],["dc.date.available","2018-11-07T09:01:49Z"],["dc.date.issued","2006"],["dc.description.abstract","Background: The placebo response rate has increased in several psychiatric disorders and is a major issue in the design and interpretation of clinical trials. The current investigation attempted to identify potential predictors of placebo response through examination of the placebo-controlled clinical trial database for escitalopram in 3 anxiety disorders and in major depressive disorder (MDD). Method: Raw data from placebo-controlled studies (conducted from 2002 through the end of 2004) of escitalopram in patients meeting DSM-IV criteria for MDD and anxiety disorders (generalized anxiety disorder [GAD], social anxiety disorder [SAD], panic disorder) were used. Potential predictors examined were type of disorder, location of study, dosing regimen, number of treatment arms, gender of patients, and duration and severity of disorder. Results: Placebo response (defined as the percent decrease from baseline in the reference scale) was higher in GAD and MDD studies conducted in Europe (p < .0001 and p = .0006, respectively) and was not associated with gender or duration of episode. In GAD, the placebo response rate was higher in a European fixed-dose study, which also had more treatment arms. In SAD and in U.S. specialist-treated MDD, a higher placebo response rate was predicted by decreased baseline disorder severity. Conclusion: Additional work is needed before definitive recommendations can be made about whether standard exclusion criteria in clinical trials of antidepressants, such as mild severity of illness, maximize medication-to-placebo differences. This analysis in a range of anxiety disorders and MDD suggests that there may be instances in which the predictors of placebo response rate themselves vary across different conditions."],["dc.identifier.isi","000242432300011"],["dc.identifier.pmid","17196054"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24524"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]